Immupharma raises £8.3mln for Lupuzor™ trials & early stage pipeline

8th February 2016 - 4:11 pm

ImmuPharma’s Chairman, Tim McCarthy, talks to Proactive Investor about the recent £8.3 million fundraising and progress on the Company’s lead drug, Lupuzor™ through its pivotal Phase III, trial.

Share this article